Current small cell lung cancer treatment in China

Author(s): Shi Y, Xing P, Fan Y, Zhang X, Hu C, et al.


Background The treatment status of small cell lung cancer (SCLC) in Mainland China has never been reported; therefore, this study is the first multicenter survey investigating the status of epidemiology and treatment options of SCLC in Mainland China. Methods Two questionnaires were designed to obtain information in 12 medical centers in five major Chinese cities. The hospital information questionnaire was designed to outline SCLC patients' characteristics and treatment preferences in each medical institution, and the patient information questionnaire collected detailed treatment information of 298 SCLC cases in these hospitals. Results SCLC represented 13.7% and 18.3% of all lung cancer patients in 2005 and 2010, respectively. Clinical management of SCLC follows mainstream clinical guidelines in general. The most widely applied first-line treatment mode for limited-stage patients was combined chemoradiotherapy (66.2%), while 77.0% of the extensive-stage patients received chemotherapy alone as initial treatment. Etoposide with cisplatin or carboplatin were the most accepted first-line chemotherapy regimens. The objective response rate was 58.3% after first-line chemotherapy and 23% of the patients who responded well to first-line treatment received prophylactic cranial irradiation. As for second-line chemotherapy, single regimen topotecan or a combined regimen containing topotecan were preferred (53.0%). Conclusions The treatment options indicated in our study are in accordance with the international clinical guidelines, which is valuable for the improvement of future guidelines, health care standard, and even the better distribution of health care resources in China.

Similar Articles

Trends in incidence of small cell lung cancer and all lung cancer

Author(s): Riaz SP, Lüchtenborg M, Coupland VH, Spicer J, Peake MD, et al.

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1pathway

Author(s): Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Author(s): Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, et al.

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Author(s): Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Author(s): Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, et al.

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

Author(s): Muenst S, Schaerli AR, Gao F, Däster S, Trella E, et al.

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas

Author(s): Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, et al.